Source: Annual Congress 2002 - Bronchial responsiveness, nebulization, devices and airway inflammation
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Lipniunas, J. Westfal, L. Asking (Lund, Sweden). Dose proportionality of in vitro fine particle dose for dry powder inhaler combination products. Eur Respir J 2002; 20: Suppl. 38, 3356

Member's Comments

No comment yet.

Related content which might interest you: Ex-vivo emitted dose characteristics for combination formulations in dry powder inhalers (DPI) Source: Eur Respir J 2003; 22: Suppl. 45, 472s Year: 2003 In vitro dosage emission for different flow rates from a combination of eformoterol and budesonide in a dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 134s Year: 2001 Variability of budesonide (BUD) fine particle dose (FPD) delivered through two multiple dose dry powder inhalers (MDPI) Source: Eur Respir J 2004; 24: Suppl. 48, 582s Year: 2004 Formoterol: a new pMDI CFC free formulation. cumulative dose safety versus a dry powder Source: Eur Respir J 2003; 22: Suppl. 45, 473s Year: 2003 Impact of critical handling errors on delivered budesonide/formoterol dose in dry powder inhalers – An in vitro study Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 Performance characteristics of a multi dose dry powder inhaler (MDPI) with respect to the use of different deaggregation systems Source: Eur Respir J 2004; 24: Suppl. 48, 582s Year: 2004 In vitro testing of two budesonide dry powder inhalers at different flow rates Source: Eur Respir J 2001; 18: Suppl. 33, 101s Year: 2001 A study to evaluate the therapeutic equivalence of a new multidose budesonide dry powder inhaler with a conventional budesonide dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001 Clinical equivalence of budesonide delivered via two dry powder inhalers Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005 The genuair® inhaler, a novel multidose dry powder inhaler, demonstrates consistent aerodynamic precision Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009 Efficacy and safety of salbutamol delivered via a novel multidose dry powder inhaler in comparison with two conventional dry powder inhalers and a pMDI in asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 50s Year: 2001 The genuair® inhaler: a novel multidose dry powder inhaler for the delivery of various types of inhalation powder Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009 Comparison of the release characteristics of formoterol dihydrate powder for inhalation delivered through two different types of multidose dry powder inhalers (MDPI) Source: Eur Respir J 2005; 26: Suppl. 49, 126s Year: 2005 In vitro comparison of dose accuracy of two budesonide/formoterol dry powder inhalers Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Equivalence testing of salbutamol dry powder inhalers by in vitro impaction Source: Eur Respir J 2001; 18: Suppl. 33, 100s Year: 2001 Once-daily budesonide: clinical equivalence of two dry powder inhalers (DPIs) Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005 Gamma-scintigraphic evaluation of the delivered dose, lung deposition rate and distribution pattern of 99mTc-labelled tiotropium via dry powder inhaler Source: Eur Respir J 2003; 22: Suppl. 45, 475s Year: 2003 Inhalation parameters from an integrated electronic multidose dry powder inhaler (eMDPI) Source: International Congress 2018 – Asthma: clinical screening tools Year: 2018 Reliability of inhalation therapy through a multidose dry powder inhaler Source: Annual Congress 2007 - Respiratory issues in primary care Year: 2007 Comparison of a formoterol multiple dose dry powder inhaler (MDPI) with a formoterol single dose dry powder inhaler (SDPI) in patients with moderate to severe asthma Source: Eur Respir J 2004; 24: Suppl. 48, 260s Year: 2004